HIV–1 Infection Detection Assay for Seroconverted HIV–1 Vaccine Recipients

Hana Golding, Surender Khurana (FDA/CBER)
Licensing Contact: Michael Shmilovich; 301/435–5019; shmilovm@mail.nih.gov.
Available for licensing and commercial distribution is an assay method and kit having diagnostic peptide fragments derived from human immunodeficiency virus-1 (HIV–1). The new serology assay includes HIV–1 peptide fragments epitopes that map to HIV–1 GAG–p6, and gp41 genes. These epitopes are broadly reactive with early sera from HIV infected individuals, do not illicit protective antibodies, do not illicit immunologic cytotoxicity and are readily removable from current and future HIV–1 candidates. The assay is advantageous in detecting HIV–1 early breakthrough infections in seroconverted vaccine recipients while being able to distinguish between individuals with bona fide breakthrough infections versus non-HIV infected vaccine recipients presenting only vaccine borne antibodies. For example, 90% of vaccine recipients receiving a Canarpyox construct expressing a plurality of HIV antigens (Env, Gag, Pol, HIV Protease, Nef) followed by an envelope protein boost, scored positive in FDA licensed enzyme immunoassay, rapid test, and Western blot (Marta-Louise Ackers et al., J Infect Dis. 187:879 (2003)). Such seroconversion has a negative impact on phase III efficacy trials of prophylactic HIV vaccines that require early detection of breakthrough infections and also exclude non-HIV infected vaccine recipients from the pool of potential blood donors.

Flow-Through, Thermal-Expansion-Compensated Microcells for Analytical Transmission Infrared and Other Light Spectroscopies

Edward Mertz (NICHD), James Sullivan (ORS)
effective electroelution of a protein from a gel band to an agarose filled slot. The drum is rotated to receive each band individually. Migrating SDS linearized proteins are electrophoresed into the receptacle slot drum. The drum is rolled until each protein of interest is separated. Agarose plugs are lifted from the drum slots; enzymatically dissolved, and loaded directly onto a MALDI spectrometer. Between two agarose layers, gel free collection chambers can be formed inside the drum providing solution phase fraction collection.

**FIG. 1**


**Simultaneous HDL/LDL/Total Lipoprotein Single Tube Homogeneous Assay**

Alan T. Remaley, Maureen Sampson, Gyorgy Csako (CC)


**Licensing Contact:** Michael Shmilovich; shmilovm@mail.nih.gov.

Available for licensing and commercialization is a device for sequentially eluting proteins and peptides. The device comprises a separation medium having an outlet, and a collector having a first receptacle and second receptacle that can be sequentially brought into contact with the outlet of the separation medium by translating (rotating) the first receptacle and the second receptacle in relation to the outlet of the separation medium. The invention is adaptable to capillary electrophoresis as well. Multiple sequential protein transfer from SDS–PAGE gel to a mass spectrometer is made possible. Separated protein bands sequentially obtained are electroeluted into low melting agarose plugs distributed along the surface of a plastic drum. The multiple costly tests were performed in order to determine low-density lipoprotein LDL–C and HDL–C by measuring total-C, total triglyceride, and HDL–C. That method of testing had limitations and was complex. Using this methodology, the homogeneous assay for HDL–C does not require physically separating HDL. The new assay developed is efficient, less costly, and compares favorably to current assays for HDL–C, total cholesterol, and triglyceride. This technology may also be used to simplify the procedure for the point of care testing of hyperlipidemia.


Steven M. Furgason, 
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 04–22151 Filed 10–1–04; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Substance Abuse and Mental Health Services Administration**

**Center for Substance Abuse Prevention Correction of Meeting Notice**

Pursuant to Pub. L. 92–463, notice is hereby given of a correction of a notice of a meeting of the Substance Abuse Prevention (CSAP) National Advisory Council to be held in October 2004.

Public notice was given in the Federal Register on September 27, 2004 (Volume 69, Number 186, page 57711) that the CSAP National Advisory Council would be meeting on October 5 and 6, 2004 at The Times Building, One Times Square, Third Floor, New York, New York. The place for this meeting has subsequently changed to The Renaissance New York Hotel Times Square, Two Times Square, 714 Seventh Avenue at W. 48th Street, New York, New York. The agenda and date of the meeting and contact for additional information remain as announced.


Toian Vaughn,

SAMHSA Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 04–22339 Filed 10–1–04; 8:45 am]

**BILLING CODE 4162–20–P**